November 29, 2022
  • Boston Scientific announced it entered a definitive agreement to acquire Apollo Endosurgery for a cash price of $10 per share to reflect an enterprise value of approximately $615 million. Apollo Endosurgery anticipates net sales of approximately $76 million in the fiscal year 2022 with significant growth of its endoscopic suturing system franchise. Boston Scientific expects to complete the transaction in the first half of 2023. (Press release here)